Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs

European Journal of Endocrinology

Volumn 152, Issue 1, 2005, Pages 61-66

  Petrossians, Patrick ^a   Borges Martins, Liliane ^a   Espinoza, Consuelo ^b   Daly, Adrian ^a   Betea, Daniela ^a   Valdes Socin, Hernan ^a   Stevenaert, Achille ^a   Chanson, Philippe ^b   Beckers, Albert ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYPOPHYSIS ADENOMA; INTERMETHOD COMPARISON; MALE; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; ADENOMA; ADOLESCENT; BLOOD; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REVIEW; SECRETION;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 13244255682     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01824     Document Type: Article

References (18)

1. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J & Giustina A. Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism 2002 87 4054-4058.
2. Fahlbusch R, Honegger J & Buchfelder M. Surgical management of acromegaly. Endocrinology and Metabolism Clinics of North America 1992 21 669-692.
3. Freda PU. Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018.
4. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiminez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F & Webb SM. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clinical Endocrinology 2000 53 577-586.
5. Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003 58 387-399.
6. Wilcox RR. Fundamentals of Modern Statistical Methods, New York: Springer, 2001.
7. Yuen KK. The two sampled trimmed t for unequal population variances. Biometrika 1974 61 165-170.
8. Ihaka R & Gentleman R. R: a language for data analysis and graphics. Journal of Computational and Graphical Statistics 1996 5 299-314.
9. Wilcox RR. Introduction to Robust Estimation and Hypothesis Testing. San Diego, CA: Academic Press, 1997.
10. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavron S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1210-1211.
11. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Javis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
12. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology 2002 87 4554-4563.
13. Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegalic study group. Archives of Internal Medicine 1991 151 1573-1578.
14. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L & Kleinberg DL. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3034-3040.
15. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I & Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism 2001 86 2779-2786.
16. Baldelli R, Colao, A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G & Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism 2000 85 4099-4103.
17. Ayuk J, Stewart SE, Stewart PM & Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 4142-4146.
18. Stevenaert A & Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism 1996 45 (8 Suppl 1) 72-74.